statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update

Agenus Inc. (Agenus) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agenus Inc. - AGEN

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agenus Inc. - AGEN SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agenus Inc...

AGEN Investors Have Opportunity to Join Agenus Inc. Securities Fraud Investigation with the Schall Law Firm

AGEN Investors Have Opportunity to Join Agenus Inc. Securities Fraud Investigation with the Schall Law Firm AGEN Investors Have Opportunity to Join Agenus Inc. Securities Fraud Investigation with the...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. (Agenus or the Company) (NASDAQ: AGEN) for...

Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer

Agenus Inc. (NASDAQ: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the results of its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug...

Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference

Agenus Inc. (Agenus) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results from an investigator-sponsored trial (IST) of botensilimab and...

Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies

Agenus Inc. (Agenus) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Cancer Therapy Evaluation Program (CTEP) is accepting Letters...

Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors

Agenus Inc. (Agenus) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, is pleased to announce the appointment of Dr. Jennifer Buell to its Board of...

Nature Medicine Reports Agenus Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50

Agenus has published results from a groundbreaking clinical trial in Nature Medicine, revealing the potential of a novel immunotherapy combination for treating microsatellite stable metastatic...

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Volume	760,652.00
52-Wk High	$32.00
52-Wk Low	$4.78

AGEN Agenus Inc

About

Feed

News

Sentiment

Earnings

Fundamentals